Sequana Medical NV develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, and internationally. The company offers alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; and Direct Sodium Removal (DSR) for the treatment of fluid overload spread across the body. Sequana Medical NV was founded in 2006 and is headquartered in Gent, Belgium.
Frequently asked questions
What sector does Sequana Medical NV (SEQUA) operate in?
Sequana Medical NV belongs to the Healthcare sector and operates in the Medical Devices industry.
What is Sequana Medical NV (SEQUA) current stock price?
As of the latest data, Sequana Medical NV stock price is €0.61, with a previous close of €0.61.
What is Sequana Medical NV (SEQUA) current market capitalization?
Sequana Medical NV market cap is approximately 47.76 million.
What is Sequana Medical NV (SEQUA) Earnings Per Share (EPS)?
The trailing EPS is -€1.23, and the forward EPS is -€0.37.
Does Sequana Medical NV (SEQUA) pay dividends?
No. Sequana Medical NV does not pay a dividend.
What is Sequana Medical NV (SEQUA) beta (volatility) score?
Sequana Medical NV has a beta of -0.287, indicating lower volatility than the overall market.